Classification of Companion Diagnostics: A New Framework for Biomarker-Driven Patient Selection.

Ther Innov Regul Sci · 2022 · PMC8854277 · PMID 34841493

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Hence, EGFR mutation can be regarded as a predictive biomarker with respect to Gifitinib and the endpoints ORR and PFS with highly significant results on the corresponding interaction.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.